Boy With Muscle-Wasting Disease Wins Access to Lifesaving New Drug

Dr. Rachel Mendez MD, Medical Science Writer

✨ Why this is good news

Duchenne Muscular Dystrophy is a genetic disease that causes muscles to weaken and waste away, often shortening lives.

First NHS-approved option.Before this, eligible patients like Ben had no drug available on the NHS to slow Duchenne’s progression. Now Givinostat offers a real chance to preserve muscle strength and delay disability.
Slows muscle decline.Givinostat targets the underlying inflammation and fibrosis that damage muscles. This means boys may stay mobile and independent for longer, instead of facing rapid loss of function.
One family’s victory for all.After Ben’s father campaigned for a year, national approval now makes the drug widely available across the NHS. Dozens of other families with eligible sons will benefit without having to fight the same battle.
Extends life expectancy.People with Duchenne typically live only into their 20s or 30s. By slowing the disease, Givinostat could help patients like Ben gain extra years of life and quality time with loved ones.

A 12-year-old boy battling Duchenne Muscular Dystrophy is set to receive a groundbreaking new treatment after his father’s year-long campaign succeeded in securing national approval. The drug, Givinostat, has been shown to slow the progression of the muscle-wasting condition, and will now be widely available across the NHS for eligible patients like Ben from Henley-on-Thames.

Duchenne Muscular Dystrophy is an inherited genetic condition that causes progressive muscle weakness and increasing disability. According to the NHS, people with the condition typically live only into their 20s or 30s. Givinostat, which was previously limited to an early access program in certain NHS trusts, has demonstrated in clinical trials that it can significantly slow the disease's advancement. Ben’s father Alex explained that his son can still walk but uses a wheelchair for longer distances. “The possibility that he would be able to walk and get out of his chair and be amongst his friends through his whole school career I think will have a huge positive impact on him, his mental health, his inclusion and our family as well,” he said.

The approval by the National Institute for Health and Care Excellence means that Ben and other eligible patients will no longer face regional disparities in access. Alex described the fight as “incredibly hard,” noting that over the past 14 to 16 months, the campaign “pretty much brought me to my knees at times.” But he added, “Coming out the other side of it now is a sense of relief.” Oxford University Hospitals, Ben’s local trust, has already prepared for the rollout. Chief medical officer Andrew Brent confirmed that governance is in place and additional staff have been recruited to start treating eligible patients with Givinostat within weeks.

While Alex acknowledged that “there’s still work to be done,” the family now looks forward to Ben receiving treatment that could preserve his mobility and independence through his school years. The decision marks a hopeful turning point for families affected by Duchenne Muscular Dystrophy, offering a proven therapy that can slow the condition and improve quality of life for children who otherwise face a relentless decline.

This article is for informational purposes only and does not constitute medical advice. The information presented is based on published research and official announcements. Always consult a qualified healthcare professional before making any medical decisions.